439 related articles for article (PubMed ID: 32823229)
21. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
[TBL] [Abstract][Full Text] [Related]
22. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S
Oncol Ther; 2024 Mar; ():. PubMed ID: 38502426
[TBL] [Abstract][Full Text] [Related]
24. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
25. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C
Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713
[TBL] [Abstract][Full Text] [Related]
27. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
Necchi A; Cucchiara V; Grivas P; Bratslavsky G; Jacob J; Spiess PE; Sokol ES; Killian JK; Lin D; Ramkissoon S; Huang RSP; Madison RW; Venstrom JM; Schrock AB; Danziger N; Decker B; Gjoerup O; Graf RP; Oxnard GR; Tukachinsky H; Ross JS
Cancer; 2021 Dec; 127(24):4557-4564. PubMed ID: 34379803
[TBL] [Abstract][Full Text] [Related]
28. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract][Full Text] [Related]
29. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Mack PC; Keller-Evans RB; Li G; Lofgren KT; Schrock AB; Trabucco SE; Allen JM; Tolba K; Oxnard GR; Huang RSP
Oncologist; 2024 Feb; ():. PubMed ID: 38401173
[TBL] [Abstract][Full Text] [Related]
30. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
31. The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
Lee JK; Hazar-Rethinam M; Decker B; Gjoerup O; Madison RW; Lieber DS; Chung JH; Schrock AB; Creeden J; Venstrom J; Alexander B; Oxnard GR
Clin Cancer Res; 2022 Feb; 28(4):728-737. PubMed ID: 34753780
[TBL] [Abstract][Full Text] [Related]
32. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
34. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I-IV Non-Small Cell Lung Cancer.
Jiang J; Adams HP; Yao L; Yaung S; Lal P; Balasubramanyam A; Fuhlbrück F; Tikoo N; Lovejoy AF; Froehler S; Fang LT; Achenbach HJ; Floegel R; Krügel R; Palma JF
J Mol Diagn; 2020 Feb; 22(2):228-235. PubMed ID: 31837429
[TBL] [Abstract][Full Text] [Related]
35. Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS; Li G; Tolba K; Bourla AB; Schulze K; Gadgil R; Fine A; Lofgren KT; Graf RP; Oxnard GR; Daniel D
JTO Clin Res Rep; 2022 Sep; 3(9):100386. PubMed ID: 36089920
[TBL] [Abstract][Full Text] [Related]
36. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
[TBL] [Abstract][Full Text] [Related]
37. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhan J; Zhao X; Chen X; Xiao L; Wu K; Ma Y; Li M; Yang Y; Fang W; Zhao H; Zhang L
BMC Med; 2021 Oct; 19(1):223. PubMed ID: 34592968
[TBL] [Abstract][Full Text] [Related]
38. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
39. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
40. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
